These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 38879608)

  • 21. Overcoming graft rejection in heavily transfused and allo-immunised patients with bone marrow failure syndromes using fludarabine-based haematopoietic cell transplantation.
    Srinivasan R; Takahashi Y; McCoy JP; Espinoza-Delgado I; Dorrance C; Igarashi T; Lundqvist A; Barrett AJ; Young NS; Geller N; Childs RW
    Br J Haematol; 2006 May; 133(3):305-14. PubMed ID: 16643433
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Alemtuzumab with fludarabine and cyclophosphamide reduces chronic graft-versus-host disease after allogeneic stem cell transplantation for acquired aplastic anemia.
    Marsh JC; Gupta V; Lim Z; Ho AY; Ireland RM; Hayden J; Potter V; Koh MB; Islam MS; Russell N; Marks DI; Mufti GJ; Pagliuca A
    Blood; 2011 Aug; 118(8):2351-7. PubMed ID: 21518925
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Analysis of allogeneic hematopoietic stem cell transplantation with high-dose cyclophosphamide-induced immune tolerance for severe aplastic anemia.
    Guo Z; Gao HY; Zhang TY; Liu XD; Yang K; Lou JX; He XP; Zhang Y; Chen P; Chen HR
    Int J Hematol; 2016 Dec; 104(6):720-728. PubMed ID: 27709450
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Fludarabine, cyclophosphamide, antithymocyte globulin, with or without low dose total body irradiation, for alternative donor transplants, in acquired severe aplastic anemia: a retrospective study from the EBMT-SAA Working Party.
    Bacigalupo A; Socie' G; Lanino E; Prete A; Locatelli F; Locasciulli A; Cesaro S; Shimoni A; Marsh J; Brune M; Van Lint MT; Oneto R; Passweg J;
    Haematologica; 2010 Jun; 95(6):976-82. PubMed ID: 20494932
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Engraftment of heavily transfused patients with severe aplastic anemia with a fludarabine-based regimen.
    Wang SB; Li L; Pan XH; Hu DM; Peng LH; Liu L; Xie ZJ; Yin B; Sun XJ; Yu J; Liang Y
    Clin Transplant; 2013; 27(2):E109-15. PubMed ID: 23387380
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Fludarabine and cyclophosphamide based reduced intensity conditioning (RIC) regimens reduce rejection and improve outcome in Indian patients undergoing allogeneic stem cell transplantation for severe aplastic anemia.
    George B; Mathews V; Viswabandya A; Kavitha ML; Srivastava A; Chandy M
    Bone Marrow Transplant; 2007 Jul; 40(1):13-8. PubMed ID: 17450183
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Alternative Donor Transplantation with High-Dose Post-Transplantation Cyclophosphamide for Refractory Severe Aplastic Anemia.
    DeZern AE; Zahurak M; Symons H; Cooke K; Jones RJ; Brodsky RA
    Biol Blood Marrow Transplant; 2017 Mar; 23(3):498-504. PubMed ID: 28013015
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Allogeneic hematopoietic stem cell transplantation for aplastic anemia with pre-transplant conditioning using fludarabine, reduced-dose cyclophosphamide, and low-dose thymoglobulin: A KSGCT prospective study.
    Kako S; Kanda Y; Onizuka M; Aotsuka N; Usuki K; Tachibana T; Kobayashi T; Kato J; Yano S; Shimizu H; Shono K; Tanaka M; Tsukamoto S; Mori T; Yamazaki E; Najima Y; Hangaishi A; Hoshino T; Watanabe R; Matsumoto K; Okamoto S;
    Am J Hematol; 2020 Mar; 95(3):251-257. PubMed ID: 31804748
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Long-term follow-up of allogeneic stem cell transplantation in patients with severe aplastic anemia after conditioning with cyclophosphamide plus antithymocyte globulin.
    Kröger N; Zabelina T; Renges H; Krüger W; Kordes U; Rischewski J; Schrum J; Horstmann M; Ayuk F; Erttmann R; Kabisch H; Zander AR
    Ann Hematol; 2002 Nov; 81(11):627-31. PubMed ID: 12454700
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Allografting in patients with severe, refractory aplastic anemia using peripheral blood stem cells and a fludarabine-based conditioning regimen: the Mexican experience.
    Gómez-Almaguer D; Vela-Ojeda J; Jaime-Pérez JC; Gutiérrez-Aguirre CH; Cantú-Rodríguez OG; Sobrevilla-Calvo P; Rivas-Vera S; Gómez-Rangel JD; Ruiz-Argüelles GJ
    Am J Hematol; 2006 Mar; 81(3):157-61. PubMed ID: 16493614
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A fludarabine-based dose-reduced conditioning regimen followed by allogeneic stem cell transplantation from related or unrelated donors in patients with myelodysplastic syndrome.
    Kröger N; Schetelig J; Zabelina T; Krüger W; Renges H; Stute N; Schrum J; Kabisch H; Siegert W; Zander AR
    Bone Marrow Transplant; 2001 Oct; 28(7):643-7. PubMed ID: 11704786
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A comparative study of porcine antihuman lymphocyte globulin versus antithymocyte globulin-fresenius in an allogeneic hematopoietic cell transplantation conditioning regimen for severe aplastic anemia.
    Zhang Y; Liu L; Si Y; Miao M; Qiu H; Tang X; Han Y; Fu C; Jin Z; Chen S; Sun A; Wu D
    Hematology; 2021 Dec; 26(1):741-750. PubMed ID: 34555301
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Fludarabine/Melphalan 100 mg/m
    Park HS; Lee JH; Lee JH; Choi EJ; Ko SH; Seol M; Lee YS; Kang YA; Jeon M; Lee KH
    Biol Blood Marrow Transplant; 2019 Jun; 25(6):1116-1121. PubMed ID: 30508593
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Improved outcome of patients older than 30 years receiving HLA-identical sibling hematopoietic stem cell transplantation for severe acquired aplastic anemia using fludarabine-based conditioning: a comparison with conventional conditioning regimen.
    Maury S; Bacigalupo A; Anderlini P; Aljurf M; Marsh J; Socié G; Oneto R; Passweg JR;
    Haematologica; 2009 Sep; 94(9):1312-5. PubMed ID: 19734425
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A Comparison of the Myeloablative Conditioning Regimen Fludarabine/Busulfan with Cyclophosphamide/Total Body Irradiation, for Allogeneic Stem Cell Transplantation in the Modern Era: A Cohort Analysis.
    Gooptu M; Kim HT; Ho VT; Alyea EP; Koreth J; Armand P; Ritz J; Nikiforow S; Glotzbecker BE; Nageshwar P; Soiffer RJ; Antin JH; Cutler CS
    Biol Blood Marrow Transplant; 2018 Aug; 24(8):1733-1740. PubMed ID: 29555313
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Impact of CD34 Cell Dose and Conditioning Regimen on Outcomes after Haploidentical Donor Hematopoietic Stem Cell Transplantation with Post-Transplantation Cyclophosphamide for Relapsed/Refractory Severe Aplastic Anemia.
    Arcuri LJ; Nabhan SK; Cunha R; Nichele S; Ribeiro AAF; Fernandes JF; Daudt LE; Rodrigues ALM; Arrais-Rodrigues C; Seber A; Atta EH; de Oliveira JSR; Funke VAM; Loth G; Junior LGD; Paz A; Calixto RF; Gomes AA; Araujo CES; Colturato V; Simoes BP; Hamerschlak N; Flowers ME; Pasquini R; Rocha V; Bonfim C
    Biol Blood Marrow Transplant; 2020 Dec; 26(12):2311-2317. PubMed ID: 32949751
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The use of a fludarabine-based conditioning regimen in patients with severe aplastic anemia--a retrospective analysis from three Indian centers.
    George B; Mathews V; Lakshmi KM; Melinkeri S; Sharma A; Viswabandya A; Sharma S; Das S; Ahmed R; Abraham A; Nair V; Apte S; Chandy M; Srivastava A
    Clin Transplant; 2013; 27(6):923-9. PubMed ID: 24304374
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Single non-blood-related umbilical cord blood transplantation using a reduced-intensity conditioning regimen for the treatment of severe aplastic anemia].
    Wu Y; Tang BL; Song KD; Sun GY; Pan TZ; Huang AJ; Yan BB; Zhu XY
    Zhonghua Xue Ye Xue Za Zhi; 2024 Jan; 45(1):68-73. PubMed ID: 38527841
    [No Abstract]   [Full Text] [Related]  

  • 39. Improved Outcome of a Reduced Toxicity-Fludarabine, Cyclophosphamide, plus Antithymocyte Globulin Conditioning Regimen for Unrelated Donor Transplantation in Severe Aplastic Anemia: Comparison of 2 Multicenter Prospective Studies.
    Kang HJ; Hong KT; Lee JW; Kim H; Park KD; Shin HY; Lee SH; Yoo KH; Sung KW; Koo HH; Lee JW; Chung NG; Cho B; Kim HK; Koh KN; Im HJ; Seo JJ; Jung HJ; Park JE; Lee YH; Lim YT; Lim YJ; Kim SY; Yoo ES; Ryu KH; Lee JH; Park JA; Park SK; Ahn HS;
    Biol Blood Marrow Transplant; 2016 Aug; 22(8):1455-1459. PubMed ID: 27090956
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison of outcomes after two standards-of-care reduced-intensity conditioning regimens and two different graft sources for allogeneic stem cell transplantation in adults with hematologic diseases: a single-center analysis.
    Le Bourgeois A; Mohr C; Guillaume T; Delaunay J; Malard F; Loirat M; Peterlin P; Blin N; Dubruille V; Mahe B; Gastinne T; Le Gouill S; Moreau P; Mohty M; Planche L; Lode L; Bene MC; Chevallier P
    Biol Blood Marrow Transplant; 2013 Jun; 19(6):934-9. PubMed ID: 23523970
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.